Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nipro’s Forxiga AG to Hit Shelves on September 4
Nipro said on August 19 that it will launch its authorized generic version (AG) of AstraZeneca’s SGLT2 inhibitor Forxiga (dapagliflozin propylene glycolate hydrate) on September 4.The AG, Dapagliflozin Tablets 5 mg and 10 mg “Nipro”, was added to the NHI…
To read the full story
Related Article
- Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
- Revolade, Bilanoa See First Generics in June Listing; 3 Final AGs on Roster
June 11, 2026
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
August 18, 2025
BUSINESS
- Mochida to Take Over Topiloric from Fuji Yakuhin in October
August 20, 2026
- Eisai CEO Honored by WashU Medicine for AD Contributions
August 20, 2026
- MSD Revises Airwin Label with ZENITH Trial Data
August 20, 2026
- Nipro’s Forxiga AG to Hit Shelves on September 4
August 20, 2026
- Opdivo Snares Taiwan Label Expansion for NSCLC: Ono
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…